1 Taylor CJ, Roalfe AK, Iles R, Hobbs FD. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. BMJ Open. 2014;4(4):e004675.
2 Gariani K, Perrier A, Marti C. [Performance of natriuretic peptide as a marker in patients with chronic obstructive pulmonary disease]. Rev Med Suisse. 2012;8(358):1961–2, 4–5.
3 Galinier M. BNP. NT-proBNP: lequel choisir en pratique? Réalités cardiologie. 2010.
4 Précis de biopathologie – BNP et NTproBNP. 2012.
5 Jourdain P. BNP, NT-pro-BNP: quel peptide natriurétique choisir? Revues générales. 2006;2018(Cahier 1).
6* Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
7* Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330–7.
8* Januzzi JL Jr., Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101(3A):29–38.
9* Kimmenade V, Januzzi. The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. Biomark Insights. 2007;1:143–55.
10 Jourdain P, Lefevre G, Oddoze C, Sapin V, Dievart F, Jondeau G, et al. [NT-proBNP in practice: from chemistry to medicine]. Ann Cardiol Angeiol (Paris). 2009;58(3):165–79.
11 Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43(9):1590–5.
12 Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29(4):737–44.
13 Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20):1475–80.
14 Januzzi JL, Jr. B-Type Natriuretic Peptide Testing in the Era of Neprilysin Inhibition: Are the Winds of Change Blowing? Clin Chem. 2016;62(5):663–5.
15 Nunez J, Nunez E, Robles R, Bodi V, Sanchis J, Carratala A, et al. Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol. 2008;61(12):1332–7.
16 Benmachiche M, Marques-Vidal P, Waeber G, Mean M. In-hospital mortality is associated with high NT-proBNP level. PLoS One. 2018;13(11):e0207118.
17 Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.
18* Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e61.
19 Galinier M, Berry M, Delmas C, Fournier P. [Interest of NT-proBNP in chronic heart failure follow-up]. Ann Biol Clin (Paris). 2013;71:39–45.
20 Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6(3):355–8.
21 McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10(3):198–204.
22 Tung RH, Camargo CA, Jr., Krauser D, Anwaruddin S, Baggish A, Chen A, et al. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006;48(1):66–74.